Michael Roger Ardern-Jones

Michael Roger Ardern-Jones

Auto-generated profile, based on publicly available information

Michael Roger Ardern-Jones

Clinical Experimental Sciences, Faculty of Medicine, University of Southampton , Southampton

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2013 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
LNLouise Newell
Louise Newell
MPMarta Ewa Polak
Marta Ewa Polak
JPJay Perera
Jay Perera
COCharlotte Owen
Charlotte Owen
PBPeter Boyd
Peter Boyd
MAMichael R. Ardern-Jones
Michael R. Ardern-Jones

8 March 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
CTChristos Tziotzios
Christos Tziotzios
CPChristos Petridis
Christos Petridis
NDNick Dand
Nick Dand
CAChrysanthi Ainali
Chrysanthi Ainali
JSJake R. Saklatvala
Jake R. Saklatvala
JMJohn A. McGrath
John A. McGrath
Frontal fibrosing alopecia (FFA) is a recently described inflammatory and scarring type of hair loss affecting almost exclusively women. Despite a dramatic recent increase in incidence the aetiopathogenesis of FFA remains unknown. We undertake genome-wide association studies in females from a UK cohort, comprising 844 cases and 3,760 controls, a Spanish cohort of 172 cases and 385 controls, and perform statistical meta-analysis. We observe genome-wide significant association with FFA at four genomic loci: 2p22.2, 6p21.1, 8q24.22 and 15q2.1. Within the 6p21.1 locus, fine-mapping indicates that the association is driven by theHLA-B*07:02 allele. At 2p22.1, we implicate a putative causal missense variant inCYP1B1, encoding the homonymous xenobiotic- and hormone-processing enzyme. Transcriptomic analysis of affected scalp tissue highlights overrepresentation of transcripts encoding components of innate and adaptive immune response pathways. These findings provide insight into disease pathogenesis and characterise FFA as a genetically predisposed immuno-inflammatory disorder driven byHLA-B*07:02.

21 September 2022 in Clinical & Experimental Allergy
Verified
Journal Article
Closed access
LSLouise Savic
Louise Savic
MAMichael Ardern‐Jones
Michael Ardern‐Jones
AAAnthony Avery
Anthony Avery
TCTim Cook
Tim Cook
SDSarah Denman
Sarah Denman
AWAmena Warner
Amena Warner

28 January 2021 in Eye
Verified
Journal Article
Open access
PDF file
MPMagdalena Z. Popiela
Magdalena Z. Popiela
RBRamez Barbara
Ramez Barbara
ATAndrew M. J. Turnbull
Andrew M. J. Turnbull
ECEmma Corden
Emma Corden
BMBeatriz Suarez Martinez-Falero
Beatriz Suarez Martinez-Falero
PHParwez N. Hossain
Parwez N. Hossain
Objectives: To determine the presenting features of ocular surface disease in patients with atopic dermatitis (AD) treated with dupilumab at a tertiary, university hospital. To establish the need for treatment of dupilumab-associated ocular surface disease and report any long-term effects on the ocular surface. Methods: A retrospective analysis of consecutive patients treated with dupilumab for AD between January 2017 and August 2019 was undertaken. Data were collected on demographics, incidence and type of ocular disease features, natural history and treatment. Results: A total of 50% (14/28) patients developed ocular symptoms with a mean time of onset of 6.75 (±6.1) weeks from starting dupilumab. Of these, 69% (9/13) were diagnosed with conjunctivitis associated with cicatrisation in two patients and periorbital skin changes in four. Of these nine, four had prior history of atopic keratoconjunctivitis. All were treated with topical steroids; two required additional ciclosporin drops. In all, 67% (6/9) patients went on to have on-going ocular inflammation requiring maintenance drops at a mean of 16 (±6.9) months of follow-up. All patients had improvement in their AD severity; only one patient discontinued dupilumab due to ocular side effects. Conclusion: The rate of dupilumab-associated ocular surface disease was 32%. Periorbital skin changes and conjunctival cicatrisation were noted in association with conjunctivitis. Ocular surface disease improved on topical steroids and ciclosporin but 67% of patients needed on-going treatment. Close liaison with an ophthalmologist should be considered in those patients who develop conjunctivitis or have a past history of severe ocular surface disease.

31 January 2013 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
MPMarta Ewa Polak
Marta Ewa Polak
GBG. Belgi
G. Belgi
CMC. McGuire
C. McGuire
CPC. Pickard
C. Pickard
EHEugene Healy
Eugene Healy
MAM.R. Ardern-Jones
M.R. Ardern-Jones

11 April 2011 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
MAMichael R. Ardern‐Jones
Michael R. Ardern‐Jones
PFPeter S. Friedmann
Peter S. Friedmann